Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiling Yan

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Frontiers in Immunology|September 5, 2022
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphomaHuanxin Zhang, Zhiling Yan, Ying Wang, et al.
Cancer Medicine|July 2, 2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphomaWei Sang, Ming Shi, Jingjing Yang, et al.
Science Translational Medicine|November 19, 2025
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiationJiaojiao Guo, Yaru Li, Zhiling Yan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple MyelomaYing Wang, Jiang Cao, Weiying Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ TrialJieyun Xia, Hujun Li, Zhiling Yan, et al.
The Lancet. Haematology|April 14, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trialJieyun Xia, Qian Sun, Dian Zhou, et al.
American Journal of Hematology|May 26, 2026
Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA GroupJiajia Pan, Chunmei Fu, Qing Ling, et al.
Bone Marrow Transplantation|November 25, 2025
Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisYuqian Sun, Jun Zhu, Jia Chen, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Frontiers in Immunology|September 5, 2022
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphomaHuanxin Zhang, Zhiling Yan, Ying Wang, et al.
Cancer Medicine|July 2, 2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphomaWei Sang, Ming Shi, Jingjing Yang, et al.
Science Translational Medicine|November 19, 2025
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiationJiaojiao Guo, Yaru Li, Zhiling Yan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple MyelomaYing Wang, Jiang Cao, Weiying Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ TrialJieyun Xia, Hujun Li, Zhiling Yan, et al.
The Lancet. Haematology|April 14, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trialJieyun Xia, Qian Sun, Dian Zhou, et al.
American Journal of Hematology|May 26, 2026
Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA GroupJiajia Pan, Chunmei Fu, Qing Ling, et al.
Bone Marrow Transplantation|November 25, 2025
Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisYuqian Sun, Jun Zhu, Jia Chen, et al.
Pageof 12